Bristol Myers Squibb (NYSE:BMY) Stock Price Expected to Rise, Leerink Partners Analyst Says

Bristol Myers Squibb (NYSE:BMY) had its target price hoisted by research analysts at Leerink Partners from $54.00 to $60.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ target price would suggest a potential upside of 6.36% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on BMY. BMO Capital Markets restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Guggenheim restated a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company increased their price target on Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, December 10th. Finally, Citigroup reaffirmed a “neutral” rating and set a $53.00 price objective (up from $45.00) on shares of Bristol Myers Squibb in a research note on Wednesday, January 7th. Seven analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $56.86.

Bristol Myers Squibb Trading Up 1.1%

Shares of NYSE BMY traded up $0.64 during trading on Tuesday, hitting $56.41. 1,817,860 shares of the company traded hands, compared to its average volume of 11,719,916. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The firm has a market capitalization of $114.84 billion, a P/E ratio of 19.05, a P/E/G ratio of 9.25 and a beta of 0.29. The company has a 50-day moving average price of $51.12 and a 200-day moving average price of $47.87. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, equities analysts predict that Bristol Myers Squibb will post 6.74 EPS for the current year.

Institutional Investors Weigh In On Bristol Myers Squibb

Institutional investors have recently bought and sold shares of the business. Trifecta Capital Advisors LLC acquired a new position in Bristol Myers Squibb in the second quarter worth about $25,000. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Harbor Capital Advisors Inc. boosted its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares in the last quarter. REAP Financial Group LLC grew its position in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares during the period. Finally, KERR FINANCIAL PLANNING Corp acquired a new position in Bristol Myers Squibb during the third quarter worth $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.